These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 9973516)
1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516 [TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433 [TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009 [TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753 [TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Delgado M; Jonakait GM; Ganea D Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366 [TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. MartÃnez C; Delgado M; Pozo D; Leceta J; Calvo JR; Ganea D; Gomariz RP J Leukoc Biol; 1998 May; 63(5):591-601. PubMed ID: 9581803 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. Delgado M; Ganea D J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105 [TBL] [Abstract][Full Text] [Related]
8. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. Delgado M; Sun W; Leceta J; Ganea D J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358 [TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. Martinez C; Delgado M; Gomariz RP; Ganea D J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779 [TBL] [Abstract][Full Text] [Related]
10. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. Soares MB; Titus RG; Shoemaker CB; David JR; Bozza M J Immunol; 1998 Feb; 160(4):1811-6. PubMed ID: 9469441 [TBL] [Abstract][Full Text] [Related]
11. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Ganea D; Delgado M Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014 [TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Delgado M Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537 [TBL] [Abstract][Full Text] [Related]
13. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. Delgado M; Reduta A; Sharma V; Ganea D J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654 [TBL] [Abstract][Full Text] [Related]
14. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883 [TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. Delgado M; Leceta J; Ganea D J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573 [TBL] [Abstract][Full Text] [Related]
16. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701 [TBL] [Abstract][Full Text] [Related]
17. Vasoactive Intestinal Peptide and pituary adenylate cyclase-activating polypeptide inhibit tissue factor expression in monocyte in vitro and in vivo. Lv B; Tang Y; Chen F; Xiao X Shock; 2009 Feb; 31(2):185-91. PubMed ID: 18650785 [TBL] [Abstract][Full Text] [Related]
18. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178 [TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945 [TBL] [Abstract][Full Text] [Related]
20. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Neuroimmunol; 1999 May; 96(2):167-81. PubMed ID: 10337915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]